- Home
- ABOS vs CRVS Comparison
ABOS vs CRVS Comparison
Compare ABOS & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ABOS | CRVS |
|---|---|---|
| Founded | 1996 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 113.9M | 634.0M |
| IPO Year | 2021 | 2016 |
Fundamental Metrics
Financial Performance| Metric | ABOS | CRVS |
|---|---|---|
| Price | $2.31 | $7.81 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $7.67 | ★ $13.75 |
| AVG Volume (30 Days) | 155.0K | ★ 1.6M |
| Earning Date | 11-12-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.86 | $2.54 |
| 52 Week High | $2.46 | $9.60 |
Technical Indicators
Market Signals| Indicator | ABOS | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 64.74 | 42.46 |
| Support Level | $2.01 | $7.47 |
| Resistance Level | $2.15 | $9.60 |
| Average True Range (ATR) | 0.14 | 0.54 |
| MACD | 0.03 | -0.15 |
| Stochastic Oscillator | 84.92 | 14.87 |
Price Performance
Historical ComparisonAbout ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).